Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV).
The programme identified the RSV drug treatment candidates in just 10 months, the company said in a stock exchange announcement this morning.
“AI-led drug discovery can accelerate the timeline achievable which reduces costs while also decreasing risks and providing a higher likelihood of success in bringing groundbreaking therapies to patients,” Poolbeg said.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
